人类慢性创伤性脑病的蛋白质组分析 大脑涉及蛋白质组和核糖体功能障碍 疾病进展
bioRxiv : the preprint server for biology
|February 23, 2026
概括
慢性创伤性脑病变 (CTE) 涉及蛋白质变化,特别是蛋白质体和核糖体通路,与疾病进展和头部冲击有关. 这些发现提供了关于CTE病原和潜在治疗点的见解.
科学领域:
- 神经科学是一个神经科学.
- 蛋白质组学是指蛋白质组学.
- 神经退行性疾病 神经退行性疾病
背景情况:
- 慢性创伤性脑病变 (CTE) 是一种进展性神经退行性疾病,与重复头部损伤 (RHI) 有关.
- 导致CTE进展的分子机制尚不清楚.
- 了解这些机制对于开发诊断和治疗至关重要.
研究的目的:
- 为了确定与CTE病理学和临床特征相关的蛋白质变化.
- 阐明关键的生物途径,涉及到CTE的发病.
- 为了将蛋白质组变化与疾病进展和临床结果相关联.
主要方法:
- 高通量蛋白质组学 (SomaScan 7k) 在204个背侧前额皮质样本上进行.
- 分析包括识别与CTE相关的差异表达蛋白质,tau病理和临床评分.
- 用基因组丰富分析来识别受影响的生物通路.
主要成果:
- 蛋白质组子单元蛋白和相关途径与CTE进展和接触运动持续时间有显著的关联.
- 核糖体蛋白和与高酸化 (ptau) 负担相关的通路的减少.
- 与MAPK相关的细胞信号通路显示了CTE的显著变化.
结论:
- 蛋白质组变化,特别是涉及蛋白质组和核糖体通路,是CTE进展的关键.
- 这些发现将特定的分子途径与CTE病理学和临床特征联系起来.
- 这些结果为开发CTE新型诊断和治疗提供了基础.
更多相关视频
09:00Biochemical Purification and Proteomic Characterization of Amyloid Fibril Cores from the Brain
Published on: April 28, 2022
3.8K
10:51Consensus Brain-derived Protein, Extraction Protocol for the Study of Human and Murine Brain Proteome Using Both 2D-DIGE and Mini 2DE Immunoblotting
Published on: April 10, 2014
16.8K
相关概念视频
The Proteasome
1.8K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.8K
The Proteasome
10.4K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.4K
The Proteasome
4.8K
4.8K
Proteomics
10.0K
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
10.0K
Amyloid Fibrils
12.1K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.1K
